Grant Fabry, APRN
Nurse Practitioner · Omaha, NENPI 1306527148
Payments from drug & device makers
Across 205 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$755
- Bayer$432
- Boehringer Ingelheim$378
- ANI Pharmaceuticals, Inc.$339
- Otsuka America Pharmaceutical, Inc.$228
- Calliditas Therapeutics US Inc.$206
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$54015%
- Food & beverage$3,10885%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 13 | $755 |
| Bayer | 26 | $432 |
| Boehringer Ingelheim | 26 | $378 |
| ANI Pharmaceuticals, Inc. | 43 | $339 |
| Otsuka America Pharmaceutical, Inc. | 13 | $228 |
| Calliditas Therapeutics US Inc. | 7 | $206 |
| Novartis | 12 | $204 |
| Amgen | 13 | $178 |
| Vifor Pharma, Inc. | 12 | $164 |
| AstraZeneca(2 entities) | 8 | $145 |
| Scpharmaceuticals Inc. | 6 | $100 |
| Mallinckrodt Hospital Products Inc. | 4 | $87 |
| Fresenius USA Marketing, Inc. | 5 | $82 |
| Novo Nordisk | 3 | $62 |
| Sanofi | 2 | $55 |
| Apellis Pharmaceuticals, Inc. | 2 | $47 |
| GSK | 2 | $36 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Veloxis Pharmaceuticals, Inc. | 1 | $30 |
| Akebia Therapeutics Inc | 1 | $22 |
| Nxstage Medical, Inc. | 1 | $20 |
| Mozarc Medical US LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Ascendis Pharma Endocrinology Inc | 1 | $13 |
How this compares
$3,648 in reported general payments places this provider in the 90th percentile of 924 nurse practitioner providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Torsemide | 18 | $358 |
| Tamsulosin Hcl | 12 | $227 |
| Amlodipine Besylate | 17 | $223 |
| Calcitriol | 22 | $196 |
| Furosemide | 40 | $136 |
| Losartan Potassium | 22 | $75 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Omaha
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Amanda GuggenmosOmaha$23K
- Amy YagerOmaha$15K
- Cara SchiesslerOmaha$14K
- Lindsay OneilOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.